Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a biopharmaceutical company focused on medicines for genetic diseases, and its news flow reflects both commercial activity and clinical development progress. Company updates frequently highlight Attruby (acoramidis), a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Investors following BBIO news see regular disclosures on Attruby’s commercial performance and new clinical and real-world data from the ATTRibute-CM program and its open-label extension, including analyses of variant ATTR-CM populations and specific genetic subgroups. BridgeBio also reports on late-stage pipeline milestones, such as Phase 3 results for BBP-418 in LGMD2I/R9, topline data and regulatory plans for encaleret in autosomal dominant hypocalcemia type 1, and registrational studies of infigratinib in children with skeletal dysplasias.
News items often include participation in major medical and investor conferences, where BridgeBio presents moderated digital posters, scientific analyses, and corporate updates. Additional releases cover financial and corporate developments, including quarterly business updates, equity inducement grants, royalty monetization transactions related to acoramidis, and proposed offerings of convertible senior notes.
This BBIO news page on Stock Titan aggregates these announcements so readers can review clinical data disclosures, commercial updates, financing transactions, and governance developments in one place. For investors and observers tracking genetic disease drug development and ATTR-CM therapies, the news feed provides a concise view of BridgeBio’s reported progress and key events over time.
BridgeBio Pharma (NASDAQ: BBIO) announced a collaboration with Oregon Health & Science University (OHSU) to develop investigational therapies for genetically driven conditions. This partnership extends five years of informal collaboration and aims to leverage OHSU's research capabilities to advance potential treatments for diseases like cancer. The collaboration underscores BridgeBio's commitment to rapidly translating genetic research into clinical applications, enhancing its portfolio of over 30 development programs.
BridgeBio Pharma (NASDAQ: BBIO) has announced a collaboration with The Lundquist Institute to develop treatments for genetically driven diseases and cancers. This two-year partnership aims to harness Lundquist's research capabilities and BridgeBio's resources to identify potential therapies. The partnership extends BridgeBio's network to 20 academic and research institutions, emphasizing their commitment to pioneering medicines for patients. CEO Neil Kumar expressed optimism about translating scientific discoveries into meaningful treatments.
BridgeBio Pharma (NASDAQ: BBIO) has announced a collaboration with the Canadian Glycomics Network (GlycoNet) aimed at translating glycomics research into treatments for genetic diseases. The partnership intends to foster research programs and clinical investigations, leveraging glycomics insights for therapeutic advancements. BridgeBio has previously partnered with various academic institutions, enhancing its research capabilities. This collaboration is expected to streamline the development of treatments for genetic disorders, addressing unmet medical needs.
BridgeBio Pharma (NASDAQ: BBIO) has partnered with Brown University to enhance research in genetically driven neurological disorders. The collaboration aims to advance treatment methods for complex brain diseases, leveraging Brown's neurology expertise. Under this partnership, promising discoveries will be evaluated, with opportunities for Brown scientists to take leadership roles in developing therapeutic programs. This collaboration is part of BridgeBio's strategy to translate genetic research into viable medicines, complementing its existing 20 partnerships with leading academic institutions.
BridgeBio Pharma granted restricted stock units totaling 32,691 shares to 19 new employees, as part of its 2019 Inducement Equity Plan. The awards were announced on April 5, 2021, following Nasdaq Listing Rule 5635(c)(4), which requires such grants as inducements for employees entering the company. BridgeBio focuses on developing transformative medications for genetic diseases and cancers, with a pipeline of over 30 development programs from early science to advanced clinical trials.
BridgeBio and Helsinn have entered a global collaboration to co-commercialize infigratinib for oncology, sharing profits equally. Helsinn will exclusively develop and commercialize infigratinib outside the U.S., excluding China and nearby regions. BridgeBio stands to gain over $2 billion in milestone payments. The FDA has granted Priority Review for infigratinib for cholangiocarcinoma, highlighting its potential in treating FGFR-driven cancers. This partnership aims to accelerate the launch and broaden research into infigratinib's applications.
BridgeBio Pharma (Nasdaq: BBIO) announced promising early results from a Phase 2b study of encaleret for treating Autosomal Dominant Hypocalcemia Type 1 (ADH1). Out of six participants, 100% showed normalization of blood and urine calcium levels within five days. Encaleret was reported to be well-tolerated with no serious adverse events, suggesting significant efficacy potential. The company plans to discuss regulatory pathways in 2021 to potentially become the first approved therapy for ADH1. A webcast to discuss these results is scheduled for March 22, 2021.
On March 1, 2021, BridgeBio Pharma (Nasdaq: BBIO) granted 17 new employees a total of 30,510 restricted stock units under its 2019 Inducement Equity Plan. This award serves as an incentive for new employees in alignment with Nasdaq Listing Rule 5635(c)(4). The Plan, established by BridgeBio's board in November 2019, is aimed at promoting employee engagement and retention. Founded in 2015, BridgeBio focuses on developing medicines for genetic diseases and has over 30 programs in its pipeline.
BridgeBio Pharma announced FDA approval for NULIBRY (fosdenopterin), the first therapy for molybdenum cofactor deficiency (MoCD) Type A. This ultra-rare genetic disorder affects under 150 patients globally, with a median survival age of four years. NULIBRY showed an 82% reduction in mortality risk compared to untreated patients during clinical trials, offering new hope for affected families. The approval includes Orphan Drug, Breakthrough Therapy, and Rare Pediatric Disease Designation, along with a Rare Pediatric Disease Priority Review Voucher.
BridgeBio Pharma recently completed its acquisition of Eidos Therapeutics, enhancing its ability to develop acoramidis, a promising treatment for amyloidosis cardiomyopathy. The FDA accepted its NDA for infigratinib to treat cholangiocarcinoma under Priority Review, expediting the approval process. The company initiated two new clinical trials and progressed 17 ongoing studies. As of December 31, 2020, BridgeBio held $607.1 million in cash and marketable securities, following a significant financing round that raised nearly $750 million, positioning it for upcoming product launches.